Article
Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
BMC cancer - 15 Jun 2020
Hu Guan-Hua, Cheng Yi-Fei, Lu Ai-Dong, Wang Yu, Zuo Ying-Xi, Yan Chen-Hua, Wu Jun, Sun Yu-Qian, Suo Pan, Chen Yu-Hong, Chen Huan, Jia Yue-Ping, Liu Kai-Yan, Han Wei, Xu Lan-Ping, Zhang Le-Ping, Huang Xiao-Jun
Abstract excerpt
BACKGROUND: Pediatric acute myeloid leukemia (AML) with t(8;21) (q22;q22) is classified as a low-risk group. However, relapse is still the main factor affecting survival. We aimed to investigate the effect of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on reducing recurrence and improving the survival of high-risk pediatric t(8;21) AML based on minimal residual disease (MRD)-guided treatment,...
Topics
- Adolescent
- Antineoplastic Combined Chemotherapy Protocols
- Child
- Consolidation Chemotherapy
- Core Binding Factor Alpha 2 Subunit
- DNA Mutational Analysis
- Disease-Free Survival
- Female
- Hematopoietic Stem Cell Transplantation
